Patent intelligence · US
US 10130658
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
Patent details — US 10130658
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 20, 2018
- Expiration
- Nov 15, 2038
- Applicant
- Provectus Pharmatech, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K31/352
Quick answer
US 10130658 (Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Nov 20, 2018. Expires Nov 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Provectus Pharmatech, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K31/352, A61K38/1709, A61K38/217
More from Provectus Pharmatech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 12064507
Composition and method for oral treatment of leukemia
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted
Frequently asked questions
What is US patent 10130658?
US 10130658 (Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Nov 20, 2018. Expires Nov 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10130658?
Provectus Pharmatech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 10130658 expire?
Our index shows an expiration date of Nov 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.